Epirubicin and Docetaxel in the Treatment of Patients With Metastatic Breast Cancer

NCT00193024 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

90

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Docetaxel
DRUG: Epirubicin

Sponsor

SCRI Development Innovations, LLC

Collaborators

[object Object]
[object Object]